835 related articles for article (PubMed ID: 15974913)
21. Memantine: a therapeutic approach in treating Alzheimer's and vascular dementia.
Koch HJ; Uyanik G; Fischer-Barnicol D
Curr Drug Targets CNS Neurol Disord; 2005 Oct; 4(5):499-506. PubMed ID: 16266284
[TBL] [Abstract][Full Text] [Related]
22. [Memantine: a therapeutic drug for Alzheimer's disease and the comparison with MK-801].
Kato T
Nihon Yakurigaku Zasshi; 2004 Sep; 124(3):145-51. PubMed ID: 15333987
[TBL] [Abstract][Full Text] [Related]
23. Memantine in the treatment of mild-to-moderate Alzheimer's disease.
Cosman KM; Boyle LL; Porsteinsson AP
Expert Opin Pharmacother; 2007 Feb; 8(2):203-14. PubMed ID: 17257090
[TBL] [Abstract][Full Text] [Related]
24. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence.
Danysz W; Parsons CG
Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S23-32. PubMed ID: 12973747
[TBL] [Abstract][Full Text] [Related]
25. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation.
Chen HS; Wang YF; Rayudu PV; Edgecomb P; Neill JC; Segal MM; Lipton SA; Jensen FE
Neuroscience; 1998 Oct; 86(4):1121-32. PubMed ID: 9697119
[TBL] [Abstract][Full Text] [Related]
26. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
Wenk GL
J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
[TBL] [Abstract][Full Text] [Related]
27. [Memantine: from the original brand to generics].
Titova NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):136-143. PubMed ID: 29171502
[TBL] [Abstract][Full Text] [Related]
28. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma.
Seki M; Lipton SA
Prog Brain Res; 2008; 173():495-510. PubMed ID: 18929130
[TBL] [Abstract][Full Text] [Related]
29. [The clinical relevance of memantine use].
Sobów T
Psychiatr Pol; 2004; 38(2):321-30. PubMed ID: 15307296
[TBL] [Abstract][Full Text] [Related]
30. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity.
Volbracht C; van Beek J; Zhu C; Blomgren K; Leist M
Eur J Neurosci; 2006 May; 23(10):2611-22. PubMed ID: 16817864
[TBL] [Abstract][Full Text] [Related]
31. Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine.
Kotermanski SE; Johnson JW
J Neurosci; 2009 Mar; 29(9):2774-9. PubMed ID: 19261873
[TBL] [Abstract][Full Text] [Related]
32. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity.
Chen HS; Pellegrini JW; Aggarwal SK; Lei SZ; Warach S; Jensen FE; Lipton SA
J Neurosci; 1992 Nov; 12(11):4427-36. PubMed ID: 1432103
[TBL] [Abstract][Full Text] [Related]
33. NMDA Receptor Antagonists: Repositioning of Memantine as a Multitargeting Agent for Alzheimer's Therapy.
Kabir MT; Sufian MA; Uddin MS; Begum MM; Akhter S; Islam A; Mathew B; Islam MS; Amran MS; Md Ashraf G
Curr Pharm Des; 2019; 25(33):3506-3518. PubMed ID: 31604413
[TBL] [Abstract][Full Text] [Related]
34. Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer's disease.
Yu SP; Jiang MQ; Shim SS; Pourkhodadad S; Wei L
Mol Neurodegener; 2023 Jul; 18(1):43. PubMed ID: 37400870
[TBL] [Abstract][Full Text] [Related]
35. Memantine and Kynurenic Acid: Current Neuropharmacological Aspects.
Majláth Z; Török N; Toldi J; Vécsei L
Curr Neuropharmacol; 2016; 14(2):200-9. PubMed ID: 26564141
[TBL] [Abstract][Full Text] [Related]
36. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses.
Xia P; Chen HS; Zhang D; Lipton SA
J Neurosci; 2010 Aug; 30(33):11246-50. PubMed ID: 20720132
[TBL] [Abstract][Full Text] [Related]
37. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.
Parsons CG; Stöffler A; Danysz W
Neuropharmacology; 2007 Nov; 53(6):699-723. PubMed ID: 17904591
[TBL] [Abstract][Full Text] [Related]
38. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data.
Parsons CG; Danysz W; Quack G
Neuropharmacology; 1999 Jun; 38(6):735-67. PubMed ID: 10465680
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of memantine in the treatment of dementia.
Rossom R; Adityanjee ; Dysken M
Am J Geriatr Pharmacother; 2004 Dec; 2(4):303-12. PubMed ID: 15903287
[TBL] [Abstract][Full Text] [Related]
40. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.
Kornhuber J; Weller M
Biol Psychiatry; 1997 Jan; 41(2):135-44. PubMed ID: 9018383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
